Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Intended number of patients: 63 patients in total

• Phase I: 9 patients for 3 levels
• Phase II: 50 patients plus 3 patient from Phase I at MTD level
• Plus 4 patients: considering 5% follow-up loss rate

Study design and methodology:

For phase I, 9 patients; 3 levels of bortezomib (1.0, 1.3 and 1.6 mg/m2), 3 patients at each dose level.

If escalation of bortezomib beyond 1.0 mg/m2 is not possible, the trial will be stopped.

For phase II, 53 patients (3 from phase I at MTD level); Reject when complete response rate equal or less than 12/19 or 37/53 by Simon two-stage optimal phase II design.

Treatments:

• Bortezomib:

For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.

For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks.

• CHOP2: cyclophosphamide 750mg/ m2 day 1, vincristine 1.4 mg/ m2 (max. 2 mg) day 1, doxorubicin 50 mg/ m2 day 1, prednisolone 100 mg days 1-5, every 2 weeks.
• G-CSF: Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks.

Inclusion criteria

• Histologically confirmed DLBCL
• Age 70 years or less
• Previously untreated
• Performance status: ECOG 0-2
• Advanced stage: stage III, IV, or non-contiguous stage II
• Measurable disease: 1 cm or more by spiral CT
• Normal liver function

Exclusion criteria

• Platelet count less than 75,000/microL within 14 days before enrollment.
• Absolute neutrophil count of less than 1,500/microlL within 14 days before enrollment.
• Cr more than 2.0 mg/dL and/or calculated or measured creatinine clearance less than 50 mL/min within 14 days before enrollment.
• Peripheral neuropathy of Grade 2 or worse within 14 days before enrollment.
• Hypersensitivity to bortezomib, boron or mannitol.
• Female subject is pregnant or breast-feeding.
• Other investigational drugs with 14 days before enrollment
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
• Uncontrolled or severe cardiovascular disease, including MI within 6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis